What is the current BioCardia market capitalization?
The current market capitalization of BioCardia is 2.89 M USD.
BioCardia Market capitalization 2024
BioCardia Market capitalization
2.89 M USD
Ticker
BCDA
ISIN
US09060U5074
WKN
A2PLXH
In 2024, BioCardia's market cap stood at 2.89 M USD, a -78.83% increase from the 13.67 M USD market cap in the previous year.
The BioCardia Market capitalization history
| YEAR | Market Capitalization (undefined USD) |
|---|---|
| 2023 | 0.03 |
| 2022 | 0.48 |
| 2021 | 0.88 |
| 2020 | 0.48 |
| 2019 | 0.67 |
| 2018 | 1.1 |
| 2017 | 3.51 |
| 2016 | 0.25 |
| 2015 | 0.03 |
| 2014 | 0.35 |
| 2013 | 0.36 |
| 2012 | 0.26 |
| 2011 | 0.3 |
| 2010 | 1.49 |
| 2009 | 3.17 |
| 2008 | 4.81 |
| 2007 | 0.24 |
| 2006 | 0.01 |
| 2005 | 0.02 |
| 2004 | 0.02 |
BioCardia Aktienanalyse
What does BioCardia do?
BioCardia Inc is a medical technology company based in San Carlos, California, founded in 1994. They specialize in the development of medical devices used in the treatment of heart diseases. BioCardia has three main product lines: the Helix™ Biotherapy Platform, the Morph™ Transseptal Systems, and the CYPHER Select™ Balloon Catheter. The Helix™ Biotherapy Platform was developed to treat cardiovascular diseases using regenerative medicine. The system utilizes patient's own stem cells to repair damaged heart tissue and reduce the risk of heart attacks. This therapy method can significantly improve the quality of life and survival chances of patients with heart diseases. The Morph™ Transseptal Systems are used for minimally invasive removal of blood clots. They consist of a flexible guide wire and a catheter device that allows the doctor to remove the clot in the heart without performing an open surgery. This procedure is faster, safer, and less invasive than conventional methods. The CYPHER Select™ Balloon Catheter is used to open narrowed arteries in the heart. The balloon is inserted into the artery and inflated to break up the narrowing. Then, a medication is released to prevent the recurrence of the narrowing. This procedure is minimally invasive and enables faster recovery of patients. BioCardia is also involved in clinical research and collaborates closely with renowned institutions such as the Stanford University Medical Center. Through clinical studies, BioCardia collects important data on the efficacy and safety of its products. The results of these studies are published in medical journals and contribute to the advancement of medical practice. BioCardia's business model is based on the development and commercialization of innovative medical devices for the treatment of heart diseases. The company has built a portfolio of products and platforms that allow it to specialize in various areas of cardiovascular medicine. BioCardia also utilizes partnerships and collaborations to market its products and services. Overall, BioCardia is one of the leading companies in the field of medical devices for the treatment of heart diseases. With a portfolio of innovative products and a strong presence in medical research, BioCardia is well positioned to solidify its position as a market leader in the industry. BioCardia ist eines der beliebtesten Unternehmen auf Eulerpool.com.Market capitalization Details
Exploring BioCardia's Market Capitalization
BioCardia's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.
Year-to-Year Comparison
A yearly comparison of BioCardia's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.
Impact on Investments
BioCardia's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.
Interpreting Market Capitalization Fluctuations
Variations in BioCardia’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.
Frequently Asked Questions about BioCardia stock
What is market capitalization?
The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like BioCardia.
How has the market capitalization of BioCardia developed in recent years?
The market capitalization of BioCardia has increased/decreased by -78.83% compared to the previous year.
What does market capitalization mean for investors?
The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.
Why is market capitalization an important indicator for investors?
The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.
Why does the market capitalization fluctuate?
The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.
What role does market capitalization play in the valuation of BioCardia?
In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.
Does the market capitalization influence the performance of BioCardia?
There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
Does the market capitalization of BioCardia have an influence on indices?
Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).
How much dividend does BioCardia pay?
Over the past 12 months, BioCardia paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BioCardia is expected to pay a dividend of 0 USD.
What is the dividend yield of BioCardia?
The current dividend yield of BioCardia is .
When does BioCardia pay dividends?
BioCardia pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of BioCardia?
BioCardia paid dividends every year for the past 0 years.
What is the dividend of BioCardia?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is BioCardia located?
BioCardia is assigned to the 'Health' sector.
Wann musste ich die Aktien von BioCardia kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of BioCardia from 11/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.
When did BioCardia pay the last dividend?
The last dividend was paid out on 11/19/2024.
What was the dividend of BioCardia in the year 2023?
In the year 2023, BioCardia distributed 0 USD as dividends.
In which currency does BioCardia pay out the dividend?
The dividends of BioCardia are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von BioCardia
Our stock analysis for BioCardia Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioCardia Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
